- Home
- ANVS vs INKT Comparison
ANVS vs INKT Comparison
Compare ANVS & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANVS
- INKT
- Stock Information
- Founded
- ANVS 2008
- INKT 2017
- Country
- ANVS United States
- INKT United States
- Employees
- ANVS N/A
- INKT N/A
- Industry
- ANVS Biotechnology: Pharmaceutical Preparations
- INKT Medicinal Chemicals and Botanical Products
- Sector
- ANVS Health Care
- INKT Health Care
- Exchange
- ANVS Nasdaq
- INKT Nasdaq
- Market Cap
- ANVS 55.5M
- INKT 48.7M
- IPO Year
- ANVS 2020
- INKT 2021
- Fundamental
- Price
- ANVS $2.34
- INKT $15.83
- Analyst Decision
- ANVS Strong Buy
- INKT Buy
- Analyst Count
- ANVS 4
- INKT 3
- Target Price
- ANVS $17.33
- INKT $37.50
- AVG Volume (30 Days)
- ANVS 231.9K
- INKT 87.6K
- Earning Date
- ANVS 11-07-2025
- INKT 08-14-2025
- Dividend Yield
- ANVS N/A
- INKT N/A
- EPS Growth
- ANVS N/A
- INKT N/A
- EPS
- ANVS N/A
- INKT N/A
- Revenue
- ANVS N/A
- INKT N/A
- Revenue This Year
- ANVS N/A
- INKT N/A
- Revenue Next Year
- ANVS N/A
- INKT N/A
- P/E Ratio
- ANVS N/A
- INKT N/A
- Revenue Growth
- ANVS N/A
- INKT N/A
- 52 Week Low
- ANVS $1.11
- INKT $4.56
- 52 Week High
- ANVS $10.54
- INKT $76.00
- Technical
- Relative Strength Index (RSI)
- ANVS 43.00
- INKT 53.11
- Support Level
- ANVS $2.21
- INKT $13.11
- Resistance Level
- ANVS $2.51
- INKT $15.26
- Average True Range (ATR)
- ANVS 0.13
- INKT 1.23
- MACD
- ANVS -0.01
- INKT 0.08
- Stochastic Oscillator
- ANVS 25.35
- INKT 85.26
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.